BAP1 Immunostain andCDKN2A(p16) FISH Analysis

New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?

(2016) Andrew Churg et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

p16/CDKN2A FISH in Differentiation of Diffuse Malignant Peritoneal Mesothelioma From Mesothelial Hyperplasia and Epithelial Ovarian Cancer

(2015) Tomohiro Ito et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Deletion status ofp16in effusion smear preparation correlates with that of underlying malignant pleural mesothelioma tissue

(2015) Tomoyuki Hida et al.   CANCER SCIENCE

High Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma

(2015) Masaki Nasu et al.   Journal of Thoracic Oncology

Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology

(2015) Juliana Andrici et al.   MODERN PATHOLOGY

BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations

(2015) Marta Cigognetti et al.   MODERN PATHOLOGY

p16 FISH Deletion in Surface Epithelial Mesothelial Proliferations Is Predictive of Underlying Invasive Mesothelioma

(2014) Harry Hwang et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

p16Deletion in Sarcomatoid Tumors of the Lung and Pleura

(2013) Naobumi Tochigi et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Morphology of 9p21 homozygous deletion-positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology

(2013) Shinji Matsumoto et al.   CANCER CYTOPATHOLOGY

Diagnostic Usefulness of p16/CDKN2A FISH in Distinguishing Between Sarcomatoid Mesothelioma and Fibrous Pleuritis

(2012) Di Wu et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: 2012 Update of the Consensus Statement from the International Mesothelioma Interest Group

(2012) Aliya N. Husain et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma

(2012) Yoshie Yoshikawa et al.   CANCER SCIENCE

The Predictive Role of p16 Deletion, p53 Deletion, and Polysomy 9 and 17 in Pancreatic Ductal Adenocarcinoma

(2012) Yanli Luo et al.   PATHOLOGY & ONCOLOGY RESEARCH

Loss of the Tumor Suppressor BAP1 Causes Myeloid Transformation

(2012) A. Dey et al.   SCIENCE

The Diagnostic Utility ofp16FISH and GLUT-1 Immunohistochemical Analysis in Mesothelial Proliferations

(2011) Sara E. Monaco et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Fluorescence In Situ Hybridization in the Definitive Diagnosis of Malignant Mesothelioma in Effusion Cytology

(2010) Spasenija Savic et al.   CHEST

Adaptation of a commercial fluorescent in situ hybridization test to the diagnosis of malignant cells in effusions

(2009) Carmen Flores-Staino et al.   LUNG CANCER

9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis

(2008) Fabiana Botelho de Miranda Onofre et al.   CANCER

Characterization of 9p21 copy number alterations in human melanoma by fluorescence in situ hybridization

(2008) Zsuzsa Rákosy et al.   CANCER GENETICS AND CYTOGENETICS

Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas

(2008) Simion Chiosea et al.   MODERN PATHOLOGY

Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas

(2008) Sanja Dacic et al.   VIRCHOWS ARCHIV